Zobrazeno 1 - 10
of 172
pro vyhledávání: '"Jun Ninomiya"'
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC). Methods Pa
Externí odkaz:
https://doaj.org/article/6f69a6a4de23498b91dd4a4577d0b1f8
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Programmed cell death (PCD) occurs in several forms including apoptosis and necroptosis. Apoptosis is executed by the activation of caspases, while necroptosis is dependent on the receptor interacting protein kinase 3 (RIPK3). Precise contro
Externí odkaz:
https://doaj.org/article/2056cc721a4243bf8b14c0331b0af806
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e94982 (2014)
Macrophages play diverse roles in tissue homeostasis and immunity, and canonically activated macrophages are critically associated with acute inflammatory responses. It is known that activated macrophages undergo cell death after transient activation
Externí odkaz:
https://doaj.org/article/32ddf83edec040e9b64ee154f41baa1e
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88037 (2014)
The liver is the first line of defense from environmental stressors in that hepatocytes respond to and metabolize them. Hence, hepatocytes can be damaged by stressors. Protection against hepatic cell damage and cell death is important for liver funct
Externí odkaz:
https://doaj.org/article/7bca9e756e6b41b79209b9dd26acd41b
Autor:
Giichi Takaesu, Maiko Inagaki, Keiyo Takubo, Yuji Mishina, Paul R Hess, Gregg A Dean, Akihiko Yoshimura, Kunihiro Matsumoto, Toshio Suda, Jun Ninomiya-Tsuji
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e51073 (2012)
A cytokine/stress signaling kinase Tak1 (Map3k7) deficiency is known to impair hematopoietic progenitor cells. However, the role of TAK1 signaling in the stem cell function of the hematopoietic system is not yet well defined. Here we characterized he
Externí odkaz:
https://doaj.org/article/6b707aa788c14c03ae9c4216e9ae859f
Publikováno v:
PLoS ONE, Vol 4, Iss 2, p e4561 (2009)
We have previously reported that intestinal epithelium-specific TAK1 deleted mice exhibit severe inflammation and mortality at postnatal day 1 due to TNF-induced epithelial cell death. Although deletion of TNF receptor 1 (TNFR1) can largely rescue th
Externí odkaz:
https://doaj.org/article/aa9b16abca4b47259136a1a024cdef00
Autor:
Kazuhito Sai, Aoi Nakanishi, Kimberly M. Scofield, Debra A. Tokarz, Keith E. Linder, Todd J. Cohen, Jun Ninomiya-Tsuji
Publikováno v:
Journal of Cell Science. 136
Neuroinflammation is causally associated with Alzheimer's disease (AD) pathology. Reactive glia cells secrete various neurotoxic factors that impair neuronal homeostasis eventually leading to neuronal loss. Although the glial activation mechanism in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4949dbd3ae57b487be003c0947a9155b
https://doi.org/10.1242/jcs.260102
https://doi.org/10.1242/jcs.260102
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 30:87-95
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01acbfc60058a7dde20c2a9d6dc51d03
https://doi.org/10.3804/jjabcs.30.87
https://doi.org/10.3804/jjabcs.30.87
Publikováno v:
The Journal of Cell Biology
The RIPK3-MLKL pathway protects epithelial cells from Listeria monocytogenes invasion. Sai et al. find that Listeria infection activates MLKL but does not induce its oligomerization or necroptotic cell death. Instead, Listeria-activated MLKL directly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::311e0ef07c866bfaaeb2ac2900b74761
http://europepmc.org/articles/PMC6548127
http://europepmc.org/articles/PMC6548127
Autor:
Tsuyoshi Saito, Jun Ninomiya, K Okubo, T Higuchi, Kenichi Inoue, K Kimizuka, T Nakakuma, H Yamada
Publikováno v:
Cancer Research. 79:P6-17
Background: Docetaxel, trastuzumab, and pertuzumab (DTP) therapy is established first-line therapy for patients with HER2-positive metastatic breast cancer (HER2 + MBC). However, the poor tolerability of docetaxel impedes its long-term administration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dbb4a7fbdffd0c392c326037661c9fc
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-14
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-14